Skip to main content
. Author manuscript; available in PMC: 2020 Aug 26.
Published in final edited form as: Aliment Pharmacol Ther. 2012 Mar 26;35(9):1027–1035. doi: 10.1111/j.1365-2036.2012.05059.x

Figure 2 ∣.

Figure 2 ∣

(a) Mean histology activity index scores among patients on combination therapy with lamivudine and adefovir (Lam & Adv) vs. adefovir monotherapy (Adv) at baseline, 48 weeks and 192 weeks. (b) Mean Ishak fibrosis scores among patients on combination therapy with lamivudine and adefovir (Lam & Adv) vs. adefovir monotherapy (Adv) at baseline, 48 weeks and 192 weeks.